Landolfo
Kevin P. Landolfo, Chapel Hill, NC US
Patent application number | Description | Published |
---|---|---|
20090221504 | DOSE OF AN ANGIOGENIC FACTOR AND METHOD OF ADMINISTERING TO IMPROVE MYOCARDIAL BLOOD FLOW - The present invention has multiple aspects. In one aspect, the present invention is directed to a unit dose pharmaceutical composition comprising from about 5 ng/dose to less than 135,000 ng of an angiogenic agent, typically from 5 ng to 67,500 ng. Preferably, the angiogenic agent is FGF, more preferably it is basic FGF (FGF-2). In its second aspect, the present invention is directed to a method for inducing angiogenesis, or increasing myocardial perfusion or vascular density in a patient's heart, comprising administering directly into the myocardium in an area in need, as a single injection or a series of injections, a unit dose of an angiogenic agent. It is also within the scope of the present invention that a plurality of unit dose compositions be administered directly into the myocardium at a plurality of sites in need of angiogenesis. In another aspect, the present invention is directed to a method for treating a patient for coronary artery disease, comprising administering directly into the myocardium in an area of need of angiogenesis in said patient, a unit dose (i.e., from about 5 ng to less than 135,000 ng) of an angiogenic agent. In yet another aspect, the present invention is directed to a method for treating a patient for a myocardial infarction, comprising administering directly into the myocardium in an area in need of angiogenesis in said patient, a unit dose (i.e., from about 5 ng to less than 135,000 ng) of an angiogenic agent. | 09-03-2009 |
Santo Landolfo, Torino IT
Patent application number | Description | Published |
---|---|---|
20100040602 | Antibodies against Human Cytimegalovirus (HCMV) - The present invention provides novel antibody sequences that bind human cytomegalovirus (hCMV) and neutralize hCMV infection. The novel sequences can be used for the medical management of hCMV infections, in particular for preparing pharmaceutical compositions to be used in the prophylactic or therapeutic treatment of hCMV infections. | 02-18-2010 |
20100284916 | Antibodies Against Human Cytomegalovirus (HCMV) - The present invention provides novel antibody sequences that bind human cytomegalovirus (hCMV) and neutralize hCMV infection. The novel sequences can be used for the medical management of hCMV infections, in particular for preparing pharmaceutical compositions to be used in the prophylactic or therapeutic treatment of hCMV infections. | 11-11-2010 |
20110171233 | Antibodies Against Human Cytomegalovirus (HCMV) - The present invention provides novel antibodies sequences that bind human cytomegalovirus (hCMV) and neutralize hCMV infection. The novel sequences can be used for the medical management of hCMV infections, in particular for preparing pharmaceutical compositions to be used in the prophylactic or therapeutic treatment of hCMV infections. | 07-14-2011 |
20110300529 | DETECTION OF IFI16 IN BODY FLUIDS - The present invention relates to methods for the qualitative and/or quantitative determination of interferon inducible protein 16 (IFI 16) in an extracellular form. | 12-08-2011 |
20120121623 | NOVEL ANTIPATHOGENIC PEPTIDES - The present invention relates to monomeric and multimeric peptidic compounds which have antipathogenic, in particular antiviral or/and antibacterial activity. In a preferred aspect, the peptide compounds of the invention have an activity in respect of a broad spectrum of viruses, both DNA and RNA viruses, irrespective of whether they possess virus envelope or not. Further, the present invention refers to compositions comprising said peptidic compounds for medical use, i.e. for the treatment or prevention of pathogenic, in particular viral or/and bacterial infections. | 05-17-2012 |
20130058956 | EXTRACELLULAR IFI16 AS THERAPEUTIC AGENTS - The present invention relates to the inhibition of the circulating extracellular form of the interferon inducible protein 16 (extracellular IFI16) for the treatment of diseases, particularly autoimmune and/or inflammatory disorders or infective disorders. | 03-07-2013 |
20130130970 | LACTADHERIN-DERIVED PEPTIDES AS ANTIVIRAL AGENTS - The present invention relates to monomeric and multimeric peptidic compounds which have antiviral activity, particularly against integrin-using viruses, more particularly against rotavirus. Further, the present invention refers to compositions comprising said peptidic compounds for medical use or for use as food additives. | 05-23-2013 |
Santo Landolfo, Vercelli IT
Patent application number | Description | Published |
---|---|---|
20100105086 | DIFFERENTIAL DIAGNOSIS FOR SCLERODERMA - Use of IFI16 protein, fragments or peptides thereof for differential diagnosis of the limited cutaneous form of scleroderma (Ic-SSc) in a subject suspected of or at risk of having an autoimmune disease and the corresponding method of diagnosis and kit. | 04-29-2010 |